The company is developing BB-031, a first-in-class RNA aptamer targeting von Willebrand Factor (vWF), a critical, non-redundant driver of the clot formation, propagation and stabilization. In tandem, Basking is developing BB-025, a rapid-acting complementary oligonucleotide that immediately neutralizes BB-031 pharmacological activity in the event of bleeding. Preclinical research in multiple gold-standard animal models demonstrated that BB-031 quickly establishes recanalization of blocked blood vessels in the brain, as late as 6 hours after stroke onset.
– Leading cause of long-term disability
~$240B annual US cost in 2030
BB-031 has demonstrated superiority to recombinant tissue plasminogen activator (rTPA) across multiple gold-standard experimental models. Reversal agent BB-025 expands the clinical utility of that agent by allowing for hemostatic modulation.
Improved risk-benefit profile over standard-of-care (SOC) allows:
von Willebrand factor (vWF) drives both clot formation but also pathological expansion.